NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

March 31, 2015

Arjun V. Balar, MD, oncologist, NYU Langone Medical Center, discusses the results of the phase III ASSURE trial, which compared sorafenib and sunitinib in patients with locally advanced renal cell carcinoma (RCC).

March 22, 2015

Research and development in lymphomas are proliferating at such an accelerated pace that the promise of biomarker-driven targeted therapies is moving closer toward reality.

February 23, 2015

A joint program at the NYU Langone Medical Center and the Technion-Israel Institute of Technology is positioned to attract additional, world-class support from institutions and individuals who are dedicated to eradicating cancer through focused and efficient research.

December 20, 2014

The use of multiparametric MRI in diagnosing and treating prostate cancer was explored in November during a continuing medical education course offered at the annual meeting of LUGPA

December 17, 2014

When added to standard chemotherapy, trastuzumab not only dramatically improved disease-free survival rates for patients with metastatic disease, but also resulted in a clear survival advantage unprecedented for most treatments of metastatic breast cancer.

October 31, 2014

Internationally renowned cancer biologist Benjamin G. Neel, MD, PhD, an expert in the field of cell signal transduction, has been named Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center – a National Cancer Institute-designated cancer center.

October 31, 2014

Researchers analyzed artwork, advertisements and leisure time activities to estimate historic changes in UV exposure

October 31, 2014

Researchers at NYU Langone Medical Center conclude new drug in development may offer first alternative to standard chemotherapy for T-Cell Acute Lymphoblastic Leukemia

August 27, 2014

A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.

July 29, 2014

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses treatment resistance in mesothelioma.

July 29, 2014

Douglas Kondziolka, MD, MSc, director, Gamma Knife Program, vice chair, Clinical Research, Departments of Neurosurgery and Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses updates concerning the treatment of brain metastases.

July 14, 2014

Leading experts from renowned academic centers join in one voice to encourage new perspectives in addressing brain cancer

July 14, 2014

Surgical Team at NYU Langone Medical Center Successfully Removes Life-Threatening Retroperitoneal Mass Along with Several Organs -- Staten Island Resident Expresses His Thanks

July 02, 2014

Abraham Chachoua, MD, The Jay and Isabel Fine Associate Professor of Oncology, NYU Langone Medical Center, associate director, Cancer Services, Perlmutter Cancer Center at NYU Langone, discusses ongoing clinical trials at NYU that are evaluating immunotherapy in patients with lung cancer.

June 10, 2014

Catherine M. Diefenbach, MD, assistant professor, medicine (hematology and medical oncology), Perlmutter Cancer Center at NYU Langone, explains antibody drug conjugates (ADCs)

June 04, 2014

While the combination of gemcitabine and nab-paclitaxel (Abraxane) has demonstrated survival benefits for patients with metastatic pancreatic cancer, oncologists are interested in knowing whether the regimen will transfer well into the adjuvant setting

May 30, 2014

Having a robust armamentarium to treat childhood acute lymphoblastic leukemia (ALL) is a major triumph in oncology.

May 29, 2014

Study raises concern about surgical "margins" for acral melanoma tumors, known to target the darker skins of Asians, African-Americans and Hispanics

May 28, 2014

Only a Few of More Than 109 Detected Strains Known to Cause Cancer

May 27, 2014

Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.